Fig. 5

Assessment of immunotherapy and chemotherapy in the PI3K pathway mutation and wild groups as well as pan-cancer prognostic landscape. A–G The SubMap algorithm evaluated the expression similarity between patients in the PI3K pathway mutation and wild groups and patients with different immunotherapy responses. H The TIDE algorithm predicted the distribution of immunotherapy responders in the two groups. I, J Five potential antitumor drugs specifically sensitive to patients in the PI3K pathway wild group were identified using drug sensitivity data from the CTRP (I) and PRISM (J) databases. K–M Kaplan-Meier survival analysis of the PI3K pathway mutation and wild groups in esophagogastric cancer (K), colorectal cancer (L), and melanoma (M). SubMap, subclass mapping; TIDE, tumor immune dysfunction and exclusion. *P < 0.05; **P < 0.01; ***P < 0.001